Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback